The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have jointly launched a new research fellowship in idiopathic pulmonary fibrosis.

The application process is now open; applications will be reviewed for their scientific merit, innovation, feasibility and relevance to IPF.

“Currently available medications may slow the inexorable progression of disease, but cannot halt it,” Dr. Eric White, director of translational interstitial lung disease research at the University of Michigan Medical School, said in a press release. “This research fellowship demonstrates an ongoing commitment by Boehringer Ingelheim and the ATS Foundation to support young investigators who will identify new treatments for our patients.”

White added: “In a time when it is increasingly challenging to garner NIH [National Institutes of Health] support for biomedical research, this type of research award is vitally important to both researchers and patients alike.”